1
|
Mougui A, Baba Z, Hmamouchi I, Abouqal R, Bezza A, Allali F, Bahiri R, Ghozlani I, Hassikou H, Ichchou L, Janani S, Harzy T, Niamane R, El Maghraoui A, El Bouchti I. Characteristics of Late-Onset Spondyloarthritis: Data from the Moroccan Registry of Biological Therapies in Rheumatic Diseases. Cureus 2023; 15:e39100. [PMID: 37273389 PMCID: PMC10234029 DOI: 10.7759/cureus.39100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/16/2023] [Indexed: 06/06/2023] Open
Abstract
Introduction The Assessment of SpondyloArthritis International Society (ASAS) criteria for axial and peripheral spondyloarthritis (SpA) allow for the classification of patients with an age of onset of disease of less than 45 years. However, SpA can start after this age. This study aimed to assess the characteristics of late-onset SpA (SpA>45 years) in the Moroccan registry of biological therapies in rheumatic diseases (RBSMR). Methods A cross-sectional study was conducted using the baseline data of the RBSMR. The protocol for the original RBSMR study was reviewed and approved by the Ethics Committee for Biomedical Research Mohammed V University - Rabat, Faculty of Medicine and Pharmacy of Rabat (approval number for the study was 958/09/19, and the date of approval was September 11, 2019), and all patients had given their written consent. Patients who met the 2009 ASAS criteria for SpA were included. They were divided into two groups: early-onset SpA (≤ 45 years) and late-onset SpA (>45 years). Clinical, biological, radiological, and therapy data of the two groups were compared. Statistical analysis was performed using SPSS v25 software (IBM Corp. Armonk, NY). Parameters with a p-value ≤0.05 were considered significant. Results Our population consisted of 194 patients. Thirty-one patients (16%) had late-onset SpA. Comparison between patients with early-onset (≤45 years) and late-onset SpA (>45 years) revealed that late-onset SpA had a higher tender joint count (p=0.01), a higher swollen joint count (p=0.02), depression (p=0.00), fibromyalgia (p=0.001), hypercholesterolemia (p=0.01), and a lower frequency of coxitis (p=0.008). Logistic regression analysis confirmed that late-onset SpA was associated with a higher tender joint count (OR=0.93, CI 95%: 0.88-0.98), a higher swollen joint count (OR=0.92, CI 95%: 0.85-0.99), depression ( OR=0.19, CI 95%:0.04-0.38), fibromyalgia (OR=1.75, CI 95%: 1.74-17.85), and a lower frequency of coxitis ( OR=0.29, CI 95%: 0.11-0.75). Conclusion As life expectancy increases, late-onset SpA will become increasingly common. It is therefore imperative to determine its characteristics. In the RBSMR study, late-onset SpA was associated with a high number of tender and swollen joints, depression, fibromyalgia, and a lower frequency of coxitis.
Collapse
Affiliation(s)
- Ahmed Mougui
- Rheumatology, EzarriHospital, Faculty of Medicine and Pharmacy of Marrakech, Mohammed VI University Hospital, Marrakech, MAR
| | - Zineb Baba
- Rheumatology, Arrazi Hospital, Faculty of Medicine and Pharmacy of Marrakech, Mohammed VI University Hospital, Marrakech, MAR
| | - Ihsane Hmamouchi
- Laboratory of Biostatistics, Clinical Research and Epidemiology, Mohammed V University, Rabat, MAR
| | - Redouane Abouqal
- Laboratory of Biostatistics, Clinical Research and Epidemiology., Mohammed V University, Rabat, MAR
| | - Ahmed Bezza
- Rheumatology, Military Hospital Mohammed V, Ibn Sina University Hospital, Rabat, MAR
| | - Fadoua Allali
- Rheumatology B, El Ayachi Hospital, Ibn Sina University Hospital, University Mohamed V, Rabat, MAR
| | - Rachid Bahiri
- Rheumatology A, El Ayachi Hospital, Ibn Sina University Hospital, University Mohamed V, Rabat, MAR
| | - Imad Ghozlani
- Rheumatology, Faculty of Medicine and Pharmacy, University Ibn Zohr, Agadir, MAR
| | - Hasna Hassikou
- Rheumatology, Military Hospital Moulay Ismail, Hassan II University Hospital, Meknes, MAR
| | - Linda Ichchou
- Rheumatology, Mohammed VI University Hospital, Mohammed I University, Oujda, MAR
| | - Saadia Janani
- Rheumatology, Ibn Rochd University Hospital, Casablanca, Morocco, Casablanca, MAR
| | - Taoufik Harzy
- Rheumatology, Hassan II University Hospital, Fes, MAR
| | - Redouane Niamane
- Rheumatology, Military Hospital Avicenne, Mohammed VI University Hospital, Marrakech, MAR
| | | | - Imane El Bouchti
- Rheumatology, Ezarri Hospital, Faculty of Medicine and Pharmacy of Marrakech, Mohammed VI University Hospital, Marrakech, MAR
| |
Collapse
|
2
|
Kobak S, Yildiz F, Karaarslan A, Semiz H, Orman M. Characteristics of Turkish patients with elderly onset psoriatic arthritis: A retrospective cohort study. Medicine (Baltimore) 2017; 96:e7833. [PMID: 28816983 PMCID: PMC5571720 DOI: 10.1097/md.0000000000007833] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/08/2017] [Revised: 07/07/2017] [Accepted: 07/20/2017] [Indexed: 11/26/2022] Open
Abstract
Psoriatic arthritis (PsA) is a chronic inflamatory disease characterized with axial and peripheral joints involvement. It rarely affects patients older than 65 years old.The purpose of this study is to compare and evaluate the demographic, clinical and laboratory features of elderly-onset psoriatic arthritis (EOPsA) and young-onset (YOPsA) patients.A total of 180 patients diagnosed with PsA according to CASPAR criteria and followed-up in single center were included in this study. The patients with initial symptoms started after age 65 were accepted as EOPsA. Demographic, clinic, and laboratory data and the medications which the patients received were recorded and retrospectively evaluated.Nineteen (10.5%) of 180 patients were diagnosed as EOPsA, and 161 (89.5%) patients were evaluated as YOPsA. The mean patient age was 42.1years for the YOPsA group and 68.3 years for the elderly onset group. Mean duration of disease was 5.6 years for the early onset group and 1.3 years for the elderly onset group (P = .001). Fourteen (73.3%) of 19 EOPsA patients were female and 5 of them were male. Higher rates of fatique, pain scores, comorbid diseases, and acute phase reactants elevation were detected in EOPsA patients comparing to YOPsA (P = .000, P = .000, P = .001, and P = .001, respectively). YOPsA patients have more dactilitis, nail involvement, elevated PASI scores, and smoking habitus when compared with EOPsA patients (P = .019, P = .03, P = .005, P = .004, respectively). In terms of the treatment options chosen, there was no significant difference in the use of nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids (CS), methotrexate (MTX), and sulfasalazine (SSL), but there was a more frequent use of anti-tumor necrosis factor-alpha in the YOPsA group.YOPsA and EOPsA patients may presented with different clinical and laboratory features. EOPsA patients are characterized with higher rates of fatigue, pain scores, comorbid diseases, and acute phase reactants and less dactilitis, nail involvement, and anti-TNF-alpha usage.
Collapse
Affiliation(s)
- Senol Kobak
- Istinye University Faculty of Medicine, LIV Hospital Department of Rheumatology, Istanbul
| | - Fidan Yildiz
- Medicalpark Hospital, Department of Chest Disease
| | | | - Huseyin Semiz
- Ege University Faculty of Medicine, Department of Internal Medicine
| | - Mehmet Orman
- Ege University Faculty of Medicine, Department of Statistics, Izmir, Turkey
| |
Collapse
|
3
|
Karaarslan A, Yilmaz H, Aycan H, Orman M, Kobak S. Demographic, clinical, and laboratory features of Turkish patients with late onset ankylosing spondylitis. Bosn J Basic Med Sci 2015; 15:64-7. [PMID: 26295296 DOI: 10.17305/bjbms.2015.511] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2015] [Revised: 05/23/2015] [Accepted: 05/24/2015] [Indexed: 02/06/2023] Open
Abstract
Ankylosing spondylitis (AS) is a chronic inflammatory disease, which typically begins in early decades of life with primarily axial joints involvement. This disease rarely affects patients older than 50 years of age. The aim of this study was to compare and evaluate the demographic, clinical, and laboratory features of late onset and early onset AS patients who were followed up in a single rheumatology center. A total of 339 patients who have been diagnosed with AS according to modified New York criteria were included in the study. The patients whose initial symptoms were observed after 50 years of age were accepted as late onset AS. Out of 339 patients, 27 (7.9%) were diagnosed as late onset AS and 312 (92.3%) patients were evaluated as early onset AS. Of 27 late onset patients, 10 were male and 17 were female. Delay in the diagnosis was 5.8 years for early onset AS, while it was 3.8 years for late onset AS (p = 0.001). Higher levels of acute phase reactants and more methotrexate (MTX) use were detected in early onset AS patients compared to late onset AS (p = 0.001, p = 0.007, respectively). Statistically, there was no difference between these two groups, with regard to disease clinical activity indexes, anthropometric measurement parameters, uveitis and peripheral joint involvement. In this study, we showed that early and late onset AS patients may present with different clinical, genetic, and laboratory features. Late onset AS patients are characterized with lower human leukocyte antigen-B27 sequence, less inflammatory sign, delayed diagnosis, and less MTX and anti-tumor necrosis factor alpha drug usage.
Collapse
|
5
|
Kouassi Djaha JM, Jenvrin C, Dupont MP, Steiner J, de Bandt M. [Late onset spondyloarthropathy misdiagnosed as polymyalgia rheumatica]. Rev Med Interne 2013; 34:667-70. [PMID: 23394951 DOI: 10.1016/j.revmed.2013.01.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2012] [Revised: 12/24/2012] [Accepted: 01/04/2013] [Indexed: 01/15/2023]
Abstract
PURPOSE Polymyalgia rheumatica (PMR) is a frequent cause for long-term corticosteroid therapy. Management of PMR is difficult and recommendations (regarding diagnosis and treatment) from the British Society of Rheumatology have been recently published in order to avoid false diagnosis and unnecessary corticosteroid therapy. On the other hand, late onset spondyloarthropathies are difficult to diagnose due to their various presentation (peripheral and axial manifestations, usually associated with severe systemic manifestations) and the absence of validated diagnosis criteria in the elderly. METHODS We report on eight patients, who all of them initially responding to Bird's criteria for PMR, and whose outcome was refractory PMR with multiple flares, poor therapeutic response, with inability to taper steroids. RESULTS After a mean follow-up of 25 months, a diagnosis of late onset spondyloarthropathy was done in all theses patients based on clinical history, physical examination, and spine MRI. In four of the cases the use of TNFα blockers allowed to taper corticosteroid and to control the disease. Retrospectively, the diagnosis at presentation was difficult. CONCLUSION Among PMR patients with poor response to corticosteroids and multiple flares, the possibility of a late onset spondyloarthropathy should be discussed. There is an unmet need for validated diagnosis criteria in such patients.
Collapse
Affiliation(s)
- J-M Kouassi Djaha
- Unité de rhumatologie, centre hospitalier d'Aulnay-sous-Bois, boulevard Ballanger, 93600 Aulnay-sous-Bois, France
| | | | | | | | | |
Collapse
|
7
|
Abstract
Ankylosing spondylitis is the prototype of related diseases commonly called spondylarthropathies which include reactive arthritis, psoriatic arthritis, arthritis associated with inflammatory bowel diseases (enteropathic arthritis) and undifferentiated spondylarthropathies. Ankylosing spondylitis and spondylarthropathies are generally observed in young patients but can be observed later in life or in persons >50 years of age. All the spondylarthropathy subgroups are represented in the elderly with some features particular to this age group. Indeed, radiological aspects of ankylosing spondylitis may be difficult to interpret because of the radiological changes induced by aging. Late-onset peripheral spondylarthropathies are characterised by severe disease, marked elevation of laboratory parameters of inflammation, oligoarthritis involving the lower limbs and oedema of the extremities. Psoriatic arthritis is more severe in the elderly and is associated with worse outcomes than in young patients. The clinical presentation of undifferentiated spondylarthropathy is as varied in the elderly as in young and middle-aged adults. Reactive arthritis and enteropathic arthritis are observed in the elderly more rarely. The effects of aging on drug metabolism and pharmacokinetics, together with the existence of co-morbidities and polypharmacy, are responsible for difficulties in the therapeutic management of late-onset ankylosing spondylitis or spondylarthropathies. Indeed, NSAIDs should be used with caution in older patients because of the high risk of serious gastrointestinal complications. Sulfasalazine and methotrexate have been used as disease-controlling drugs but did not prove very effective. Pamidronate and tumour necrosis factor (TNF)-alpha antagonists offer a therapeutic alternative but have not been specifically tested in the elderly. Pamidronate has been tested in young-onset ankylosing spondylitis and spondylarthropathies with conflicting results but can be used in older patients without risk of major adverse effects. TNFalpha antagonists have been adequately evaluated in ankylosing spondylitis and spondylarthropathies and are associated with dramatic improvement in clinical and biological parameters of disease activity. However, the safety profile of these agents in the elderly is not currently known and careful surveillance, in particular for the risk of infection such as tuberculosis, and/or exacerbation of chronic heart failure, is thus required when using these drugs in this age group.
Collapse
Affiliation(s)
- Eric Toussirot
- Department of Rheumatology, University Hospital Jean Minjoz, Besançon, France.
| | | |
Collapse
|